Phaseline

Targets › CYBB

CYBB (NADPH oxidase 2): drug programs, companies and trials

3 programs from 2 companies in 5 trials: 5 Phase 1; Hematology, Infectious disease, Immunology; next expected readout Jul 2027.

Catalytic subunit of the phagocyte NADPH oxidase complex that mediates the transfer of electrons from cytosolic NADPH to O2 to produce the superoxide anion (O2(-)). In the activated complex, electrons are first transferred from NADPH to flavin adenine dinucleotide (FAD) and subsequently transferred via two heme molecules to molecular oxygen, producing superoxide through an outer-sphere reaction (Probable). (UniProt, P04839)

Open in Phaseline: the race on CYBB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)gp91 Grans
mRNA-transfected granulocytes delivering functional gp91phox (NADPH oxidase component)
CYBBPhase 1Chronic Granulomatous DiseaseJul 2027
National Institute of Allergy and Infectious Diseases (NIAID)Base-edited hematopoietic stem and progenitor cells (autologous)
Base editing to repair CYBB gene mutation
CYBBPhase 1CD40L-HyperIgM Syndrome; Chronic Granulomatous Disease (CGD)Oct 2027
EnsomaEN-374
Gene therapy delivering functional CYBB gene to restore NADPH oxidase activity in neutroph
CYBBPhase 1X-Linked Chronic Granulomatous DiseaseDec 2027

Conditions

CD40L-HyperIgM Syndrome (2) Chronic Granulomatous Disease (1) Chronic Granulomatous Disease (CGD) (1) X-Linked Chronic Granulomatous Disease (1)

Modalities

protein or peptide (1), mixed (1), other (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (2) Ensoma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.